MoonLake to Acquire Remaining 49% of Subsidiary

TL;DR

MoonLake buying out its subsidiary for $100M to gain full control.

AI Summary

MoonLake Immunotherapeutics announced on September 11, 2024, that it has entered into a definitive agreement to acquire the remaining 49% stake in its subsidiary, MoonLake Therapeutics AG, for approximately $100 million. This acquisition aims to fully consolidate the operations and intellectual property of MoonLake Therapeutics AG under the parent company.

Why It Matters

This move signifies MoonLake's intent to fully control its subsidiary's assets and operations, potentially streamlining future development and strategic decisions.

Risk Assessment

Risk Level: medium — Acquisitions carry inherent risks, including integration challenges and potential overvaluation, which could impact MoonLake's financial performance.

Key Numbers

• $100 million — Acquisition Cost (Amount to acquire the remaining 49% stake in MoonLake Therapeutics AG.)
• 49% — Ownership Stake (Percentage of MoonLake Therapeutics AG being acquired.)

Key Players & Entities

• MoonLake Immunotherapeutics (company) — Registrant
• MoonLake Therapeutics AG (company) — Subsidiary being acquired
• $100 million (dollar_amount) — Acquisition price
• September 11, 2024 (date) — Date of announcement and agreement
• Helix Acquisition Corp (company) — Former company name

FAQ

Key Financial Figures

• $0.0001 — red Class A ordinary share, par value $0.0001 per share MLTX The Nasdaq Capital M

Filing Documents

• ea0214194-8k_moonlake.htm (8-K) — 28KB
• 0001213900-24-077513.txt ( ) — 195KB
• mltx-20240911.xsd (EX-101.SCH) — 3KB
• mltx-20240911_lab.xml (EX-101.LAB) — 33KB
• mltx-20240911_pre.xml (EX-101.PRE) — 22KB
• ea0214194-8k_moonlake_htm.xml (XML) — 3KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 11, 2024 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) Dorfstrasse 29 6300 Zug Switzerland (Address of Principal Executive Offices and Zip Code) 41 415108022 (Registrant's Telephone Number, Including Area Code) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Class A ordinary share, par value $0.0001 per share MLTX The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 7.01 Regulation FD Disclosure. On September 11, 2024, MoonLake Immunotherapeutics (the "Company") will be posting to its website an investor presentation to be used in the Company's September 11, 2024 Capital Markets Day event, including information regarding the Company's financial position, near-term catalysts and publication roadmap. The investor presentation and replays of the webcast will be available on the Company's website at https://ir.moonlaketx.com. The information in this current report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless specifically so incorporated. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MOONLAKE IMMUNOTHERAPEUTICS Date: September 11, 2024 By: /s/ Matthias Bodenstedt Name: Matthias Bodenstedt Title: Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR